

Resource Summary Report

Generated by [dkNET](#) on Sep 6, 2026

SK-LU-1

RRID:CVCL_0629

Type: Cell Line

Proper Citation

RRID:CVCL_0629

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0629

Proper Citation: RRID:CVCL_0629

Description: Cell line SK-LU-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:833871](#), [PMID:1855224](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:9636188](#), [PMID:12068308](#), [PMID:12794755](#), [PMID:19935656](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24135919](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-LU-1

Synonyms: SK-Lu-1, SK LU 1, SK-Lu1, SK-LU1, SKLU-1, SKLU1, SKLU01

Cross References: BTO:BTO_0003029, CLO:CLO_0009032, CLO:CLO_0009039, EFO:EFO_0022536, CLDB:cl4317, CLDB:cl4318, CLDB:cl4319,

AddexBio:C0016049/5014, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-57, BioSample:SAMN03472748, BioSample:SAMN10987792, cancercellines:CVCL_0629, CancerTools:161913, CCRID:1101HUM-PUMC000237, Cell_Model_Passport:SIDM01108, ChEMBL-Cells:ChEMBL3307447, ChEMBL-Targets:ChEMBL614913, CLS:300335, Cosmic:724877, Cosmic:909721, Cosmic:929967, Cosmic:932920, Cosmic:933576, Cosmic:1089218, Cosmic:1146944, Cosmic:1434960, Cosmic:1733129, Cosmic:1995631, Cosmic-CLP:909721, DepMap:ACH-000309, ECACC:93120835, EGA:EGAS00001000978, GDSC:909721, GEO:GSM385525, GEO:GSM385536, GEO:GSM434291, GEO:GSM513973, GEO:GSM514560, GEO:GSM784226, GEO:GSM794407, GEO:GSM827413, GEO:GSM887580, GEO:GSM888663, GEO:GSM1670434, IARC_TP53:121, ICLC:HTL96023, IGRhCellID:SK-LU-1%20GEO, IZSLER:BS TCL 81, KCLB:30057, LiGeA:CCLE_197, LINCS_LDP:LCL-1659, PharmacDB:SKLU1_1392_2019, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_0629, PubChem_Cell_line:CVCL_0629, Wikidata:Q54953746

ID: CVCL_0629

Record Creation Time: 20220427T221545+0000

Record Last Update: 20260905T182359+0000

Ratings and Alerts

No rating or validation information has been found for SK-LU-1.

No alerts have been found for SK-LU-1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 124 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Pan T, et al. (2026) MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer. Cancer research, 86(1), 146.

Zhang R, et al. (2026) Targeting a Glutamic Acid in PDE?? with Fluoromethyl-Aryl Electrophiles Impairs K-Ras Signaling. Journal of medicinal chemistry.

He D, et al. (2026) Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. Journal of the National Cancer Center, 6(3), 286.

Mendoza N, et al. (2026) Chemical Constituents of Taxodium mucronatum (Cupressaceae) and Some of Its Endophytic Fungi, and Their In Silico and In Vitro

Evaluations as SARS-CoV-2 Inhibitors and as Cytotoxic Agents. *Chemistry & biodiversity*, 23(3), e03702.

Li HS, et al. (2025) RANKL/PD-1 dual blockade demonstrates survival benefit for patients with advanced lung adenocarcinoma harboring KRAS mutations. *Cell reports. Medicine*, 6(7), 102235.

Kramer-Drauberg M, et al. (2025) Oncogenic mutant KRAS inhibition through oxidation at cysteine 118. *Molecular oncology*, 19(2), 311.

Gujar R, et al. (2025) Developing a therapeutic elastase that stimulates anti-tumor immunity by selectively killing cancer cells. *Cell reports. Medicine*, 6(11), 102446.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. *International journal of cancer*, 154(6), 1029.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Hu H, et al. (2023) Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. *The Journal of clinical investigation*, 133(2).

Nair NU, et al. (2023) A landscape of response to drug combinations in non-small cell lung cancer. *Nature communications*, 14(1), 3830.

Biswas S, et al. (2023) Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. *Immunity*, 56(11), 2570.

Kreus MA, et al. (2023) High NHLRC2 expression is associated with shortened survival in lung adenocarcinoma. *Translational lung cancer research*, 12(6), 1221.

Yoo S, et al. (2022) Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression. *Nature communications*, 13(1), 1592.

Li Y, et al. (2022) Long Noncoding RNA SNHG16 Regulates the Growth of Human Lung Cancer Cells by Modulating the Expression of Aldehyde Dehydrogenase 2 (ALDH2). *Journal of oncology*, 2022, 2411642.

Zhou X, et al. (2022) BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis. *Bioengineered*, 13(2), 2471.

Fang H, et al. (2022) miR-382-3p downregulation contributes to the carcinogenesis of lung adenocarcinoma by promoting AKT SUMOylation and phosphorylation. *Experimental and therapeutic medicine*, 24(1), 440.

Zhou L, et al. (2022) EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer. *Journal of cancer research and clinical oncology*, 148(2), 309.

Li J, et al. (2022) USP5-Becn1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity. *Nature communications*, 13(1), 7799.

Pariollaud M, et al. (2022) Circadian disruption enhances HSF1 signaling and tumorigenesis in Kras-driven lung cancer. *Science advances*, 8(39), eabo1123.